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In the last few years, a new category of anticoagulants have been developed,
the non-vitamin K oral anticoagulants (NOACs). The NOACs are of two classes:
the direct thrombin inhibitor, namely dabigatran etexilate; and the oral factor
Xa inhibitors rivaroxaban, apixaban and edoxaban, which have been proven
to be as effective and safe (and sometimes, superior) compared to warfarin
in the treatment of both atrial fibrillation (AF) and venous thromboembolism
(VTE). One major concern about their use has always been the lack of an effec-
tive antidote or reversal strategy. The objective of this editorial is to provide
an overview of the characteristics of NOAC antidotes that are in development.
Moreover, we review their likely place in the management of NOAC-related
bleeding episodes.
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1. Introduction
Vitamin K antagonists (VKAs; i.e., warfarin) have always been the mainstay of the
prevention of stroke and thromboembolism in atrial fibrillation (AF) [1]. However,
the VKAs require monitoring and have important inter- and intra-patient variability
leading to the requirement of regular International Normalized Ratio monitoring,
to ensure a high percentage of time in therapeutic range. Indeed, even if a high
time in therapeutic range is associated with the best efficacy and safety for the
VKAs [1], the search for a much more manageable oral anticoagulant agent contin-
ued, due to the VKA-related bleeding risks (especially in patients with labile Inter-
national Normalized Ratios) and the need for regular monitoring.
In the last few years, a new category of anticoagulants have been developed, the
non-vitamin K oral anticoagulants (NOACs), formerly referred to as new or novel
oral anticoagulants (Table 1) [2]. The NOACs are of two classes, the direct thrombin
inhibitor, namely dabigatran etexilate; and the oral Factor Xa inhibitors, rivaroxa-
ban, apixaban and edoxaban, which have been proved to be as effective and safe
(and sometimes, superior) compared to warfarin in the treatment of both AF [3]
and venous thromboembolism (VTE) [4].
However, when NOACs entered the current pharmacopeia, one major concern
about their use has always been the lack of an effective antidote or reversal strat-
egy [5]. With the recent announcement of the regulatory application submissions
for the approval for use of a specific reversal agent to dabigatran etexilate, called
idarucizumab [6], and the ‘Orphan Drug’ status designation for one Factor Xa
inhibitors experimental antidote, andexanet alfa, the era of specific antidotes to
NOACs seems to be increasingly more prominent.
2. A brief overview of NOACs and their bleeding risks
Dabigatran etexilate is a pro-drug with a potent thrombin direct inhibitor effect.
After its oral administration, the drug is rapidly converted to its active form, reach-
ing its peak plasma concentration within 2 h of its intake. Its half-life is around 15 h
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and the drug is almost completely excreted by the kidneys [5].
Rivaroxaban, apixaban and edoxaban are reversible inhibitors
of Factor Xa, which are highly bioavailable [5], ranging from
50% of apixaban to almost 100% of rivaroxaban. The renal
clearance of these NOACs is less marked compared to dabiga-
tran, being approximately 25% with apixaban to around 50%
with edoxaban [5].
The need for an available and effective antidote is clearly
related to the occurrence of intracranial or other major life-
threatening bleeding episodes in a patient taking a NOAC.
One of the main advantages in the adoption of NOACs
instead of VKAs in daily clinical practice has been the lower
incidence of bleeding episodes, especially intracranial hemor-
rhage (ICH) in the treatment of AF [7] or any major or clini-
cally relevant bleeding in the treatment of VTE [4].
In the RE-LY study, for example, dabigatran demonstrated
a reduced rate of ICH and life-threatening bleeding, both
with 110 and 150 mg twice a day doses, although gastrointes-
tinal bleeding was higher with the 150 mg dose [7]. Moreover,
the outcome of ICH was perhaps better in the dabigatran-
treated group, with an overall lower rate of fatal bleeding [8].
Of the Factor Xa inhibitors, rivaroxaban was associated
with similar rates of major bleeding, but with a lower rate of
ICH compared to warfarin [9]. Furthermore, both apixaban
and edoxaban were associated with lower rates of major bleed-
ing and ICH [10,11].
Finally, some recent evidence underlines how in certain
clinical settings, as in hip replacement surgery or in medically
ill patients, NOACs seem to bring a higher bleeding risk even
if in these settings the use of NOACs is less common [12].
3. Major bleeding management and reversal
strategies
As mentioned above, the major concern about NOACs has
been the management of major bleeding with an effective
reversal strategy [5,7,13]. The VKAs have a specific antidote,
which is vitamin K -- but even its administration requires
9 -- 12 h to have an appreciable effect on reversing the coagu-
lation abnormalities associated with VKA over-anticoagula-
tion. In the interim, non-specific supportive measures are
used, as described above.
Initial supportive measures, for example, immediately stop
all antithrombotic drugs, mechanical hemostasis and hemody-
namic support, are obviously recommended in all major
bleeding episodes, including those occurring with a VKA or
NOAC [5].
Oral charcoal may reduce dabigatran [13] and apixaban [14]
absorption, if administered not too long after the last drug
intake. In patients treated with dabigatran, the use of hemodi-
alysis may remove the drug from the blood, thus reversing its
anticoagulant effect [15]. Both prothrombin complex concen-
trate and activated prothrombin complex concentrate have
shown various degrees of efficacy in restoring near-normality
of various coagulation tests, and case series of their use in
NOAC bleeding cases have been reported. Some efficacy has
also been shown by the administration of recombinant
FVIIIa [13]. A summary of effective reversal strategies is found
in Table 2.
4. Direct antidotes to NOACs
In these last few years, the development of effective direct
NOACs antidotes has made great advances (Table 2) [13].
Regarding such an important clinical problem, this issue has
received a greater amount of attention recently [16].
Idarucizumab is a humanized antibody fragment that binds
to dabigatran with an affinity approximately 350 times greater
than thrombin, which has been recently submitted by Boeh-
ringer Ingelheim for regulatory approval as a specific antidote
to dabigatran.
Idarucizumab binds dabigatran, preventing its bond to
thrombin [17]. Thus, the dabigatran anticoagulant effect is
almost immediately neutralized [17]. A recently published
Phase II study [6] has shown its safety and tolerability in
human subjects. Currently on-going is the REVERSE-AD
study, that is, ‘A Phase III Case Series Clinical Study of the
Reversal of the Anticoagulant Effects of Dabigatran by Intra-
venous Administration of 5.0g Idarucizumab (BI 655075) in
Patients Treated With Dabigatran Etexilate Who Have
Uncontrolled Bleeding or Require Emergency Surgery or
Procedures’ (ClinicalTrials.gov Identifier: NCT02104947).
This study was designed to test the efficacy of idarucizumab
in patients undergoing major bleeding or emergency surgery
Table 1. NOACs general pharmacological aspects.
Rivaroxaban Apixaban Edoxaban Dabigatran
Type of drug Active agent Active agent Active agent Inactive pro-drug
Action mechanism Direct FXa inhibitor Direct FXa inhibitor Direct FXa inhibitor Direct thrombin inhibitor
Time to peak effect (hours) 2 3 -- 4 1 -- 2 1.5 -- 2
Half-life (hours) 5 -- 9 8 -- 15 9 -- 10 12 -- 17
Oral bioavailability (%) 100 50 62 6
Renal clearance (%) 33 25 35 -- 39 80
NOACs: Non-vitamin K oral anticoagulants.
M. Proietti & G. Y. H. Lip
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or procedures. The main outcome is the maximum reversal of
anticoagulant activity after a 4-h long intravenous fusion.
For the Factor Xa inhibitors, another experimental anti-
dote, andexanet alfa, has also been submitted for regulatory
approval. Even in this case, it is an engineered molecule,
obtained by manipulating and inactivating Factor Xa from a
pro-coagulant point of view, but being still able to bind the
inhibitors. Indeed, andexanet alfa has been shown to immedi-
ately reverse the anticoagulant effect of Factor Xa inhibi-
tors [18]. For example, preliminary data from a phase III
study about the treatment of human subjects taking apixaban
anticoagulant therapy (NCT02207725) show how a rapid
400 mg andexanet alfa intravenous administration results in
a complete and rapid normalization of anti-factor Xa activity
levels [19]. Moreover, recent results from the ANNEXA-A
study showed that a bolus infusion of andexanet alfa, a rapid
normalization of anti-factor Xa and thrombin levels could
be achieved [20].
Another similar study, examining the effect of andexanet
alfa on rivaroxaban activity (NCT02220725) is currently
on-going, whereas a third study on the efficacy of andexanet
alfa on all subjects taking Factor Xa inhibitors is still recruit-
ing patients (NCT02329327).
Finally, as another possible option for the reversal of
NOACs, the small molecule aripazine, now known as cirapar-
antag, seems to be promising, being able to inhibit dabigatran
and the Factor Xa inhibitors, but for now specific data about
this new agent are limited [19].
5. Expert opinion
NOACs have now entered in our daily routine practice, but
the concerns of bleeding and how to treat major bleeding epi-
sodes concern physicians who would otherwise willingly
prescribe these drugs, given their proved efficacy. All the
NOACs have half-life times that would permit loss of their
anticoagulant effect in a relatively rapid time, and the initial
supportive management strategy seems to be appropriate.
Furthermore, the use of NOACs seems to be relatively safer
than warfarin, with significantly lower rates of serious
bleeding (especially, intracranial bleeding), reducing the fear
of physicians in prescribing these drugs, notwithstanding the
lack of a specific antidote until recently.
Beyond all that, the development of new, highly engineered
molecules able to specifically block and rapidly reverse
NOACs has helped to facilitate bleeding management.
In life-threatening situations, the possibility to barely
immediately reverse the anticoagulation effect of NOACs
could have importance. For example, when hemodynamic
stability has been compromised during hemorrhagic shock,
stopping active bleeding could be necessary in trying to
stabilize vital functions.
Whilst the development of such antidotes may allow
greater dissemination of NOACs, additional large-scale
studies would be needed to prove the effectiveness of these
molecules. First of all, sample size for these studies should
be tailored according to clinical end points and not just on
pharmacokinetics end points. Second, the power of the
studies should be adequate to show superiority. Another
aspect is the absence of clinically relevant side effects and
cost-effectiveness.
Major bleeding can be related to high health-related costs.
Also the costs in terms of quality of life in patients with major
bleeding can be substantial.
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Table 2. Reversal strategies and specific antidotes for NOACs [13].
Non-specific reversal strategies Targeted antidotes
Dabigatran PCC, Activated PCC, recombinant FVIIa Idarucizumab
Rivaroxaban PCC, Activated PCC, recombinant FVIIa Andexanet Alfa, Ciraparantag
Apixaban PCC, Activated PCC, recombinant FVIIa Andexanet Alfa, Ciraparantag
Edoxaban PCC, Activated PCC, recombinant FVIIa Andexanet Alfa, Ciraparantag
PCC: Prothrombin complex concentrate; NOACs: Non-vitamin K oral anticoagulants.
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